SEQUENOM Names Harry Stylli as New CEO
Harry Stylli, an accomplished biotechnology executive, has been appointed as the new President and Chief Executive Officer of SEQUENOM, it was announced. Dr. Stylli has been elected to the Company's Board of Directors. Most recently he served as President and CEO and continues to serve as a member of the Board of Directors of Xencor, Inc.
Dr. Stylli brings to SEQUENOM broad experience in successfully translating innovative technology into commercial opportunities. He co-founded Aurora Biosciences in 1995. As Senior Vice President of Screening Technology and New Ventures, he helped raise venture and public capital, led the creation and development of Aurora's core platform, and played the key role in generating alliances with pharmaceutical companies totaling more than $300 million in committed capital. In 1999, Dr. Stylli assumed the role of Senior Vice President of Commercial Development, built a business organization that profitably grew the company's revenues to approximately $95 million and facilitated Aurora's transition from a technology to an integrated drug discovery company. In 2001, he played a pivotal role in Vertex Pharmaceuticals acquisition of Aurora for about $600 million. Following the merger, Dr. Stylli had P&L responsibility as President of Aurora Biosciences and Panvera, wholly owned subsidiaries of Vertex Pharmaceuticals.
In 2004, Dr. Stylli was elected to the Board of Directors of Xencor and was appointed Chief Executive Officer.Prior to joining Xencor, he was a founding employee and President and CEO of CovX Pharmaceuticals, where he defined the strategy and guided CovX through start-up to the pre-clinical stage that facilitated significant series B financing.
From 1987 to 1995, Dr. Stylli held various positions of increasing responsibility in the global discovery organization of Glaxo-Wellcome Research (now GlaxoSmithKline). He began his career there as a principal scientist/research manager in the advanced discovery technologies/drug technologies division during which he played a key role in assessing Affymax prior to acquisition.
Dr. Stylli currently serves as a Director of Molecular Insight Pharmaceuticals, Inc. and is an advisor to Nanosyn. He received his bachelor's of science degree from the University Of East London, United Kingdom and his Ph.D from London University's Faculty of Medicine. He later earned his master's of business administration from the U.K's Open University.
Other news from the department people
